Patient CLL Concerns

CE / CME

Addressing Patient Knowledge Gaps, Concerns, and Misperceptions About CLL

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: August 17, 2022

Expiration: August 16, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Brian Koffman
Brian Koffman, MDCM
Anthony J Perissinotti
Anthony J Perissinotti, PharmD, BCOP

Activity

Progress
1
Course Completed

References

  1. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-488.
  2. Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049-4060.
  3. Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196:947-953.
  4. Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171-1175.
  5. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.
  6. Koffman B, Dennison B, Kennard K, et al. Factors that influence treatment decision-making: perspectives of 1147 chronic lymphocytic leukemia (CLL) patients in the United States. Presented at: 60th American Society of Hematology Annual Meeting; December 1-4, 2018. Abstract 4414.
  7. Mato AR, Barrientos JC, Ghosh N, et al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry. Clin Lymphoma Myeloma Leuk. 2020;20:174-183.
  8. Koffman B, Stewart C, Avruch L, et al. Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (measurable) residual disease (MRD). Presented at: 63rd American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021. Abstract 1927.
  9. CLL Society. Data on file. 2022.